Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AC0058TA in Healthy Volunteers
NCT02847325Phase 1Completed
- Sponsor
- ACEA Therapeutics
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) comparing AC0058TA with Placebo (2 arms). Primary endpoint: Safety and tolerability determined by adverse events at 14 days. Started May 2016; status: completed.
02
Drugs
AC0058
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02847325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847325.